Meander Medisch Centrum
Welcome,         Profile    Billing    Logout  
 16 Trials 
39 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Otten, Hans-Martin
SIRIUS, NCT05375708: Systemic Therapy in Combination With Stereotactic Radiotherapy in Patients With Metastatic Colorectal Cancer up to 10 Metastatic Sites

Not yet recruiting
2
93
Europe
Stereotactic body radiation therapy (SBRT), Maintenance therapy (CAP-B or 5-FU/LV plus bevacizumab.)
UMC Utrecht
Metastatic Colorectal Cancer, Oligometastatic Disease
06/28
06/28
NCT05229471: Management of Recurrent Venous Thromboembolism During Anticoagulant Treatment in Cancer Patients - a Prospective Cohort Study

Recruiting
N/A
220
Europe
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), G. d'Annunzio University
Cancer, Venous Thromboembolism, Recurrence
12/23
12/24
Otten, HM
AMICO, NCT04754672: Aerobic Fitness or Muscle Mass Training to Improve Colorectal Cancer Outcome

Recruiting
N/A
228
Europe
Continuous aerobic and resistance exercise intervention, AE+RE, Continuous aerobic and aerobic interval exercise intervention, AE+AI
Radboud University Medical Center, UMC Utrecht, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Rijnstate Hospital, Jeroen Bosch Ziekenhuis, Flevoziekenhuis, Catharina Ziekenhuis Eindhoven, Meander Medical Center, Ziekenhuis Amstelland, Amphia Hospital, Spaarne Gasthuis, Canisius-Wilhelmina Hospital, Amsterdam UMC, location VUmc, The Netherlands Cancer Institute
Colorectal Cancer, Chemotherapeutic Toxicity, Survivorship, Lifestyle
03/26
12/26
Consten, Esther CJ
IBIZA-1, NCT05498051 / 2021-006700-32: Fluorescent Sentinel Lymph Node Identification in Colon Carcinoma Using Submucosal Bevacizumab-800CW.

Completed
N/A
5
Europe
Sentinel lymph node identification, SLN
Meander Medical Center, Meander Medisch Centrum
Colonic Neoplasms, Sentinel Lymph Node, Fluorescence, Colorectal Neoplasms
02/23
06/23
CAPP, NCT04755179: Identification of the Optimal Treatment Strategy for Complex Appendicitis in the Pediatric Population

Recruiting
N/A
1308
Europe
Laparoscopic appendectomy, Open appendectomy, Non-operative treatment, Direct appendectomy
Ramon Gorter, ZonMw: The Netherlands Organisation for Health Research and Development, Amsterdam UMC, location VUmc
Appendicitis, Appendix Mass, Appendicitis Perforated
05/23
07/23
IBIZA-2, NCT05497726 / 2021-006796-41: Fluorescent Sentinel Lymph Node Identification in Colon Carcinoma Using Intravenous Bevacizumab-800CW

Completed
N/A
5
Europe
Sentinel lymph node detection using intravenous bevacizumab-800CW
Meander Medical Center, Meander Medisch Centrum
Colorectal Neoplasms, Colon Neoplasm, Sentinel Lymph Node, Fluorescence
07/23
10/23
ProTex, NCT06430931: Biological OviTex Versus Synthetic Graft in Robotic Prolapse Surgery

Recruiting
N/A
184
Europe
Minimal invasive abdominal prolapse surgery using Polypropylene mesh, Ventral mesh rectopexy, Sacrocolporectopexy, Minimal invasive abdominal prolapse surgery using OviTex 1S permanent mesh
Meander Medical Center, Health Holland
Colorectal Disorders, Prolapse, Prolapse Rectal, Prolapse Genital, Prolapse Pelvic, Rectocele, Prolapse Uterus, Cystocele, Enterocele, Prolapse Bladder, Prolapse; Cervix
07/26
07/26
A1Check, NCT05810207: the External Validation of a Machine Learning Model Predicting Colorectal Anastomotic Leakage

Recruiting
N/A
1000
Europe
Colorectal resection
Freek Daams, SAS Institute
Anastomotic Leak, Anastomotic Leak Large Intestine, Anastomotic Complication, Anastomotic Leak Rectum
07/24
12/24
Bloemendal, Hj
DRUP, NCT02925234 / 2015-004398-33: The Drug Rediscovery Protocol ( Trial)

Recruiting
2
1550
Europe
Panitumumab, Vectibix, Olaparib, Lynparza, Dabrafenib, Tafinlar, Nilotinib, Tasigna, Trametinib, Mekinist, Erlotinib, Tarceva, Trastuzumab and Pertuzumab (combination treatment), Herceptin + Perjeta, Vemurafenib and Cobimetinib (combination treatment), Zelboraf + Cotellic, Vismodegib, Erivedge, Regorafenib, Stivarga, Nivolumab, Opdivo, Afatinib, Giotrif, Dabrafenib and trametinib, Tafinlar and Mekinist, Ribociclib, Kisqali, Lenvatinib, Lenvima, Pembrolizumab, Keytruda, Durvalumab, MEDI4736, Rucaparib, Rubraca, Axitinib, Inlyta, Palbociclib, Ibrance, Crizotinib, Xalkori, Sunitinib, Sutent, Cabozantinib, Cabometyx, Abemaciclib, Verzenios, Alectinib, Alecensa, Atezolizumab and Bevacizumab, Tecentriq and Avastin, Ipilimumab and nivolumab, Yervoy and Opdivo, Entrectinib, Rozlytrek, Talazoparib, Talzenna, Dacomitinib, Vizimpro, Lorlatinib, Lorviqua, Erdafitinib, Balversa, Alpelisib, Piqray, Niraparib, Zejula, Pemigatinib, Pemazyre, Selpercatinib, Retsevmo, Tepotinib, Tepmetko
The Netherlands Cancer Institute, Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb, Novartis, Roche Pharma AG, Merck Sharp & Dohme LLC, Boehringer Ingelheim, Ipsen, Eisai Inc., Pfizer, Clovis Oncology - Pharma and, Eli Lilly and Company, Janssen, LP, GlaxoSmithKline, Incyte Corporation, Dutch Cancer Society, Stelvio for Life
Cancer, Tumors, Neoplasm, Neoplasia
09/27
12/27
Shankar-Hari, Manu
VACIRiSS, NCT03565159: Pneumococcal Vaccination to Accelerate Immune Recovery in Sepsis Survivors

Completed
4
214
Europe
Prevenar 13, Sodium Chloride 0.9%
Guy's and St Thomas' NHS Foundation Trust, National Institute for Health Research, United Kingdom
Sepsis
08/23
08/23
REMAP-CAP, NCT02735707 / 2015-002340-14: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

Recruiting
3
20000
Europe, Canada, Japan, US, RoW
Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, IFN-β1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, acetylsalicylic acid, P2Y12 inhibitor, Clopidogrel, Prasugrel, Ticagrelor, No simvastatin, Simvastatin, Placebo, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Ramipril, Lisinopril, Perindopril, Enalapril, Trandolapril, Captopril, Angiotensin Receptor Blockers, Losartan, Valsartan, Candesartan, Irbesartan, Telmisartan, Olmesartan, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Paxlovid, Remdesivir, Nirmatrelvir/ritonavir + remdesivir
UMC Utrecht, Australian and New Zealand Intensive Care Research Centre, Medical Research Institute of New Zealand, Unity Health, Berry Consultants, Global Coalition for Adaptive Research, University of Pittsburgh Medical Center, Intensive Care National Audit & Research Centre, St. Marianna University School of Medicine, National Intensive Care Surveillance MORU, National University Hospital, Singapore
Community-acquired Pneumonia, Influenza, COVID-19
02/26
02/28
Dijkhorst-Oei, Lioe-Ting
NCT06383390: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Renal Function in Adults Living With Obesity (TRIUMPH-OUTCOMES)

Recruiting
3
10000
Europe, Canada, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Overweight and Obesity
02/29
02/29
SURMOUNT-MMO, NCT05556512: A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

Active, not recruiting
3
15374
Europe, Canada, Japan, US, RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Obesity, Overweight
10/27
10/27
KRAKEN, NCT05563246: A Study of LY3473329 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events

Completed
2
233
Europe, Japan, US, RoW
LY3473329, Placebo
Eli Lilly and Company
Lipoprotein Disorder
03/24
03/24
Sommeijer, D
AMICO, NCT04754672: Aerobic Fitness or Muscle Mass Training to Improve Colorectal Cancer Outcome

Recruiting
N/A
228
Europe
Continuous aerobic and resistance exercise intervention, AE+RE, Continuous aerobic and aerobic interval exercise intervention, AE+AI
Radboud University Medical Center, UMC Utrecht, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Rijnstate Hospital, Jeroen Bosch Ziekenhuis, Flevoziekenhuis, Catharina Ziekenhuis Eindhoven, Meander Medical Center, Ziekenhuis Amstelland, Amphia Hospital, Spaarne Gasthuis, Canisius-Wilhelmina Hospital, Amsterdam UMC, location VUmc, The Netherlands Cancer Institute
Colorectal Cancer, Chemotherapeutic Toxicity, Survivorship, Lifestyle
03/26
12/26
PLCRC, NCT02070146: Prospective Data Collection Initiative on Colorectal Cancer

Recruiting
N/A
50000
Europe
Dutch Colorectal Cancer Group
Colorectal Cancer
01/50
01/51
Siemerink, E
SEQUEL-Breast, NCT05392608: SEQUence of Endocrine Therapy in Advanced Luminal Breast Cancer

Recruiting
2
130
Europe
Alpelisib 150 MG Oral Tablet [Piqray], Piqray, Fulvestrant, Faslodex
Borstkanker Onderzoek Groep, Novartis Pharma B.V., BOOG Study Center
Neoplasm, Breast, Congenital, Familial and Genetic Disorders
12/24
03/28
DRUP, NCT02925234 / 2015-004398-33: The Drug Rediscovery Protocol ( Trial)

Recruiting
2
1550
Europe
Panitumumab, Vectibix, Olaparib, Lynparza, Dabrafenib, Tafinlar, Nilotinib, Tasigna, Trametinib, Mekinist, Erlotinib, Tarceva, Trastuzumab and Pertuzumab (combination treatment), Herceptin + Perjeta, Vemurafenib and Cobimetinib (combination treatment), Zelboraf + Cotellic, Vismodegib, Erivedge, Regorafenib, Stivarga, Nivolumab, Opdivo, Afatinib, Giotrif, Dabrafenib and trametinib, Tafinlar and Mekinist, Ribociclib, Kisqali, Lenvatinib, Lenvima, Pembrolizumab, Keytruda, Durvalumab, MEDI4736, Rucaparib, Rubraca, Axitinib, Inlyta, Palbociclib, Ibrance, Crizotinib, Xalkori, Sunitinib, Sutent, Cabozantinib, Cabometyx, Abemaciclib, Verzenios, Alectinib, Alecensa, Atezolizumab and Bevacizumab, Tecentriq and Avastin, Ipilimumab and nivolumab, Yervoy and Opdivo, Entrectinib, Rozlytrek, Talazoparib, Talzenna, Dacomitinib, Vizimpro, Lorlatinib, Lorviqua, Erdafitinib, Balversa, Alpelisib, Piqray, Niraparib, Zejula, Pemigatinib, Pemazyre, Selpercatinib, Retsevmo, Tepotinib, Tepmetko
The Netherlands Cancer Institute, Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb, Novartis, Roche Pharma AG, Merck Sharp & Dohme LLC, Boehringer Ingelheim, Ipsen, Eisai Inc., Pfizer, Clovis Oncology - Pharma and, Eli Lilly and Company, Janssen, LP, GlaxoSmithKline, Incyte Corporation, Dutch Cancer Society, Stelvio for Life
Cancer, Tumors, Neoplasm, Neoplasia
09/27
12/27
Rodenburg, CJ
CAIRO5, NCT02162563 / 2013-005435-24: Treatment Strategies in Colorectal Cancer Patients With Initially Unresectable Liver-only Metastases

Recruiting
3
564
Europe
FOLFOX/ FOLFIRI with bevacizumab, - bevacizumab, - irinotecan, - leucovorin, - 5-fluorouracil, - oxaliplatin, FOLFOXIRI with bevacizumab, FOLFOX/ FOLFIRI with panitumumab, - panitumumab
Dutch Colorectal Cancer Group
Colorectal Cancer, Liver Metastases
08/22
07/25
Smet, Bart de
STAP-Delta, NCT04422236: A Post-market, Observational Registry With the easyEndoTM Universal Linear Cutting Stapler in Laparoscopic Bariatric Surgery

Active, not recruiting
N/A
200
Europe
easyEndoTM Universal Linear Cutting Stapler and reloads (Ezisurg Medical)
Duomed
Obesity, Roux-en-Y Gastric Bypass, Gastrectomy, Mini Gastric Bypass
04/25
05/25
Herder, Judith
NCT03564197: 18F-PD-L1 PET/CT in Nivolumab Treated Patients With NSCLC

Recruiting
N/A
80
Europe
18F-PD-L1, tracer
The Netherlands Cancer Institute, Bristol-Myers Squibb
NSCLC Stage IV
12/23
12/24
Consten
NCT04101773: Napoleon Trial: Optimal Treatment for Recurrent Haemorrhoidal Disease

Not yet recruiting
N/A
558
Europe
RBL versus sutured mucopexy versus haemorrhoidectomy.
Maastricht University Medical Center, ZonMw: The Netherlands Organisation for Health Research and Development
Hemorrhoids
03/23
03/23
Nes, Anneke van Lynden- van
BioDay, NCT03549416: Registry: Data Collection Regarding the Use of New Systemic Treatment Options in Patients With Atopic Dermatitis

Recruiting
N/A
1200
Europe
UMC Utrecht, Academisch Ziekenhuis Groningen, Sanofi, AbbVie, Eli Lilly and Company, LEO Pharma
Atopic Dermatitis
12/28
12/28
Dodewaard, JM van
CrEATE, NCT06434896: Circulating Tumor DNA Based Adjuvant Chemotherapy in Stage II Colon Cancer Patients: the MEDOCC- Trial

Recruiting
N/A
1320
Europe
ctDNA analysis after surgery
UMC Utrecht, Personal Genome Diagnostics (PGDx), The Netherlands Cancer Institute
Circulating Tumor DNA, Recurrence, Colon Cancer Stage II
03/35
03/35
ORCHESTRA, NCT01792934: Chemotherapy and Maximal Tumor Debulking of Multi-organ Colorectal Cancer Metastases

Recruiting
N/A
478
Europe
XELOX regimen according to standard procedures, FOLFOX regimen according to standard procedures, Surgery, radiofrequency ablation (RFA), transarterial chemo-embolization using irinotecan drug-eluted beads ((DEBIRI-)TACE), stereotactic body radiation therapy (SBRT), Bevacizumab, tumor biopsy
Radboud University Medical Center, Erasmus Medical Center
Multi-organ Metastatic Colorectal Cancer
07/23
07/25
PRO-RCC, NCT05326620: National PROspective Infrastructure for Renal Cell Carcinoma

Recruiting
N/A
2000
Europe
PROspective Renal Cancer Cohort Foundation, Comprehensive Cancer Centre The Netherlands, Merck Sharp & Dohme LLC, Bristol-Myers Squibb, Ipsen
Renal Cancer, Renal Cell Carcinoma, Renal Cell Cancer Metastatic
01/30
01/30
PLCRC, NCT02070146: Prospective Data Collection Initiative on Colorectal Cancer

Recruiting
N/A
50000
Europe
Dutch Colorectal Cancer Group
Colorectal Cancer
01/50
01/51
Gulik, Laura van
REMAP-CAP, NCT02735707 / 2015-002340-14: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

Recruiting
3
20000
Europe, Canada, Japan, US, RoW
Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, IFN-β1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, acetylsalicylic acid, P2Y12 inhibitor, Clopidogrel, Prasugrel, Ticagrelor, No simvastatin, Simvastatin, Placebo, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Ramipril, Lisinopril, Perindopril, Enalapril, Trandolapril, Captopril, Angiotensin Receptor Blockers, Losartan, Valsartan, Candesartan, Irbesartan, Telmisartan, Olmesartan, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Paxlovid, Remdesivir, Nirmatrelvir/ritonavir + remdesivir
UMC Utrecht, Australian and New Zealand Intensive Care Research Centre, Medical Research Institute of New Zealand, Unity Health, Berry Consultants, Global Coalition for Adaptive Research, University of Pittsburgh Medical Center, Intensive Care National Audit & Research Centre, St. Marianna University School of Medicine, National Intensive Care Surveillance MORU, National University Hospital, Singapore
Community-acquired Pneumonia, Influenza, COVID-19
02/26
02/28
Klein, S
FaR-RMS, NCT04625907 / 2018-000515-24: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma

Recruiting
1/2
1672
Europe, RoW
Irinotecan, Actinomycin D, Dactinomycin, Doxorubicin, Ifosfamide, Vincristine, Vinorelbine, Cyclophosphamide, Temozolomide, radiotherapy, Regorafenib
University of Birmingham
Rhabdomyosarcoma
06/30
06/30
Schaik, C van
NCT01898117 / 2013-001484-23: Triple-B Study;Carboplatin-cyclophosphamide Versus Paclitaxel With or Without Atezolizumab as First-line Treatment in Advanced Triple Negative Breast Cancer

Active, not recruiting
2
304
Europe
Carbo/cyclo, Carboplatin, Cyclophosphamide, Carbo/cyclo + atezolizumab, Atezolizumab, Paclitaxel, Paclitaxel + Atezolizumab
The Netherlands Cancer Institute, Borstkanker Onderzoek Groep, Roche Pharma AG
Breast Cancer
12/24
12/30
Mosterd, Arend
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

Recruiting
3
12500
Europe, Canada, Japan, US, RoW
Lepodisiran Sodium, LY3819469, Placebo
Eli Lilly and Company
Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)
03/29
03/29
Widener, Nancy
ASTER, NCT05171049 / 2021-003076-14: A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE

Recruiting
3
1655
Europe, Canada, Japan, US, RoW
Abelacimab, MAA868, Apixaban, Eliquis
Anthos Therapeutics, Inc., Itreas
Venous Thromboembolism, Deep Venous Thrombosis, Pulmonary Embolism
06/25
09/25
MAGNOLIA, NCT05171075 / 2021-003085-12: A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE

Recruiting
3
1020
Europe, Canada, US, RoW
Abelacimab, MAA868, Dalteparin, Fragmin
Anthos Therapeutics, Inc., Itreas
Venous Thromboembolism, Deep Venous Thrombosis, Pulmonary Embolism
06/25
09/25
Baas, J
SEQUEL-Breast, NCT05392608: SEQUence of Endocrine Therapy in Advanced Luminal Breast Cancer

Recruiting
2
130
Europe
Alpelisib 150 MG Oral Tablet [Piqray], Piqray, Fulvestrant, Faslodex
Borstkanker Onderzoek Groep, Novartis Pharma B.V., BOOG Study Center
Neoplasm, Breast, Congenital, Familial and Genetic Disorders
12/24
03/28
Weel, Vincent van
EASYII, NCT05586503: - E-tegra Stent Graft System - Imaging Cohort

Recruiting
N/A
25
Europe
ECG-gated CTAs
JOTEC GmbH
Vascular Aneurysm
12/23
10/29
Sikkenk, Daan
IBIZA-1, NCT05498051 / 2021-006700-32: Fluorescent Sentinel Lymph Node Identification in Colon Carcinoma Using Submucosal Bevacizumab-800CW.

Completed
N/A
5
Europe
Sentinel lymph node identification, SLN
Meander Medical Center, Meander Medisch Centrum
Colonic Neoplasms, Sentinel Lymph Node, Fluorescence, Colorectal Neoplasms
02/23
06/23
IBIZA-2, NCT05497726 / 2021-006796-41: Fluorescent Sentinel Lymph Node Identification in Colon Carcinoma Using Intravenous Bevacizumab-800CW

Completed
N/A
5
Europe
Sentinel lymph node detection using intravenous bevacizumab-800CW
Meander Medical Center, Meander Medisch Centrum
Colorectal Neoplasms, Colon Neoplasm, Sentinel Lymph Node, Fluorescence
07/23
10/23
Majoie, Leonie IM
UPDATE, NCT05704205: The Trial (Uvb Phototherapy in Dermatology for ATopic Eczema)

Recruiting
N/A
316
Europe
NB-UVB phototherapy, Narrowband ultraviolet B phototherapy, Optimal topical therapy, OTT, Optimal local therapy
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), ZonMw: The Netherlands Organisation for Health Research and Development
Atopic Dermatitis Eczema, Atopic Dermatitis
06/26
12/26
Boom, Marije
ProTex, NCT06430931: Biological OviTex Versus Synthetic Graft in Robotic Prolapse Surgery

Recruiting
N/A
184
Europe
Minimal invasive abdominal prolapse surgery using Polypropylene mesh, Ventral mesh rectopexy, Sacrocolporectopexy, Minimal invasive abdominal prolapse surgery using OviTex 1S permanent mesh
Meander Medical Center, Health Holland
Colorectal Disorders, Prolapse, Prolapse Rectal, Prolapse Genital, Prolapse Pelvic, Rectocele, Prolapse Uterus, Cystocele, Enterocele, Prolapse Bladder, Prolapse; Cervix
07/26
07/26

Download Options